ATE445401T1 - Verwendung von opioid-rezeptorantagonisten zur prävention und/oder behandlung von erkrankungen im zusammenhang mit dem target calcineurin - Google Patents

Verwendung von opioid-rezeptorantagonisten zur prävention und/oder behandlung von erkrankungen im zusammenhang mit dem target calcineurin

Info

Publication number
ATE445401T1
ATE445401T1 AT05742958T AT05742958T ATE445401T1 AT E445401 T1 ATE445401 T1 AT E445401T1 AT 05742958 T AT05742958 T AT 05742958T AT 05742958 T AT05742958 T AT 05742958T AT E445401 T1 ATE445401 T1 AT E445401T1
Authority
AT
Austria
Prior art keywords
prevent
receptor antagonists
opioid receptor
diseases related
treat diseases
Prior art date
Application number
AT05742958T
Other languages
English (en)
Inventor
Helmut Schmidhammer
Original Assignee
Alcasynn Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcasynn Pharmaceuticals Gmbh filed Critical Alcasynn Pharmaceuticals Gmbh
Application granted granted Critical
Publication of ATE445401T1 publication Critical patent/ATE445401T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT05742958T 2004-05-12 2005-05-12 Verwendung von opioid-rezeptorantagonisten zur prävention und/oder behandlung von erkrankungen im zusammenhang mit dem target calcineurin ATE445401T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04011293A EP1595541A1 (de) 2004-05-12 2004-05-12 Verwendung von Opioid-Rezeptor Antagonisten zur Vorbeugung und/oder Behandlung von Krankheiten die im zusammenhang mit den Angrifftspunkt Calcineurin stehen
PCT/EP2005/005176 WO2005107752A2 (en) 2004-05-12 2005-05-12 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin

Publications (1)

Publication Number Publication Date
ATE445401T1 true ATE445401T1 (de) 2009-10-15

Family

ID=34924978

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05742958T ATE445401T1 (de) 2004-05-12 2005-05-12 Verwendung von opioid-rezeptorantagonisten zur prävention und/oder behandlung von erkrankungen im zusammenhang mit dem target calcineurin

Country Status (14)

Country Link
US (1) US20070167474A1 (de)
EP (2) EP1595541A1 (de)
JP (2) JP2007537198A (de)
CN (1) CN1997369B (de)
AT (1) ATE445401T1 (de)
AU (1) AU2005239831A1 (de)
CA (1) CA2566398A1 (de)
DE (1) DE602005017145D1 (de)
ES (1) ES2334042T3 (de)
MX (1) MXPA06013128A (de)
NO (1) NO20065551L (de)
RU (1) RU2006143770A (de)
WO (1) WO2005107752A2 (de)
ZA (1) ZA200609337B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011516464A (ja) 2008-03-31 2011-05-26 サン・ファーマシューティカル・インダストリーズ・リミテッド モルフィナン類似体の改良された調製方法
WO2009132313A2 (en) * 2008-04-25 2009-10-29 Progenics Pharmaceuticals, Inc. Morphinan derivatives of organic and inorganic acids
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
EP2641588B1 (de) 2012-03-23 2017-11-22 Induchem Holding AG Verwendung von Agonisten des delta-Opiodrezeptors in der Kosmetik und Dermakosmetik
KR101694879B1 (ko) * 2014-08-01 2017-01-12 주식회사 인트론바이오테크놀로지 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도
EP3197346B1 (de) * 2014-09-22 2020-02-26 National Health Research Institutes Verwendung von 5-methoxytryptophan als diagnosemittel von entzündungskrankheiten
US10807995B2 (en) 2018-07-13 2020-10-20 Alkermes Pharma Ireland Limited Thienothiophene compounds for long-acting injectable compositions and related methods
US10799496B2 (en) 2018-07-13 2020-10-13 Alkermes Pharma Ireland Limited Naphthylenyl compounds for long-acting injectable compositions and related methods
US10975099B2 (en) 2018-11-05 2021-04-13 Alkermes Pharma Ireland Limited Thiophene compounds for long-acting injectable compositions and related methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI942499A7 (fi) * 1992-09-29 1994-07-27 Toray Industries Indolijohdannainen, menetelmä sen valmistamiseksi ja sen lääkekäyttö
SE9401728D0 (sv) * 1994-05-18 1994-05-18 Astra Ab New compounds II
KR20030060771A (ko) * 2000-04-28 2003-07-16 메모리얼 슬로안-케터링 캔서 센터 국소용 마취제/아편양약물 제제 및 이들의 용도
ATE292625T1 (de) 2000-10-31 2005-04-15 Rensselaer Polytech Inst 8-substituierte 2,6-methano-3-benzazocine und 3- substituierte morphinane als opioidrezeptorbindende agenzien
MXPA05002983A (es) 2002-09-18 2005-06-22 Univ Missouri Analogos de opiato selectivos del receptor opioide d.

Also Published As

Publication number Publication date
JP2012254986A (ja) 2012-12-27
ZA200609337B (en) 2008-08-27
US20070167474A1 (en) 2007-07-19
NO20065551L (no) 2007-02-05
RU2006143770A (ru) 2008-06-20
CN1997369B (zh) 2011-12-21
WO2005107752A2 (en) 2005-11-17
ES2334042T3 (es) 2010-03-04
JP2007537198A (ja) 2007-12-20
WO2005107752A3 (en) 2006-06-01
CA2566398A1 (en) 2005-11-17
EP1595541A1 (de) 2005-11-16
DE602005017145D1 (de) 2009-11-26
CN1997369A (zh) 2007-07-11
EP1755604B1 (de) 2009-10-14
AU2005239831A1 (en) 2005-11-17
EP1755604A2 (de) 2007-02-28
MXPA06013128A (es) 2007-04-27

Similar Documents

Publication Publication Date Title
ATE517882T1 (de) Chinolinderivate
ATE390925T1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
WO2007002667A3 (en) Azaindazole compounds and methods of use
EA201000946A1 (ru) Бициклические производные для применения при лечении состояний, связанных с андрогенным рецептором
CL2008001932A1 (es) Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.
EP2155203A4 (de) Azaindazol-verbindungen und anwendungsverfahren
EA201070841A1 (ru) НОВЫЕ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ
MX344308B (es) Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso.
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
EA200701296A1 (ru) 3,5-дизамещенные и 3,5,7-тризамещенные 3h-оксазоло- и 3h-тиазоло[4,5-d] пиримидин-2-оны и их пролекарства
WO2007073432A3 (en) Piperidine derivatives and methods of use
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
CY1124346T1 (el) ΠΑΡΑΓΩΓΑ ΧΡΩΜΑΝΙΟΥ, ΙΣΟΧΡΩΜΑΝΙΟΥ ΚΑΙ ΔΙΥΔΡΟΪΣΟΒΕΝΖΟΦΟΥΡΑΝΙΟΥ ΩΣ mGluR2-APNHTIKOI ΑΛΛΟΣΤΕΡΙΚΟΙ ΔΙΑΜΟΡΦΩΤΕΣ, ΣΥΝΘΕΣΕΙΣ, ΚΑΙ ΧΡΗΣΗ ΑΥΤΩΝ
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
DE602005017145D1 (de) Verwendung von opioid-rezeptorantagonisten zur prävention und/oder behandlung von erkrankungen im zusammenhang mit dem target calcineurin
ATE478856T1 (de) Spirobenzodioxole und deren verwendung als cb1- antagonisten
BR0315462A (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação
CY1118486T1 (el) Λαπατινιμπη για τη θεραπεια του καρκινου
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
TW200732304A (en) Piperidine derivatives
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
BRPI0409505A (pt) compostos como antagonistas do receptor crf1
TW200700067A (en) Substituted aryl 1,4-pyrazine derivatives
EA201291114A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-a]ПИРИДИНА
MX2010004313A (es) Compuestos para inhibir la actividad de quinesina de la proteina de quinesina del huso.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1755604

Country of ref document: EP